How Can Outcomes Be Improved for Older Patients With Hodgkin Lymphoma?
Mené sur 1 299 patients atteints d'un lymphome hodgkinien, dont 117 patients d'âge supérieur à 60 ans, cet essai évalue la faisabilité et l'efficacité de quatre cycles d'un protocole de chimiothérapie ABDV (doxorubicine, bléomycine, vinblastine et dacarbazine) chez les patients âgés
Older age has consistently been identified as an independent adverse prognostic factor for Hodgkin lymphoma (HL) survival in population-based studies and clinical trials in the last several decades. In the 1970s and 1980s, 5-year event-free survival or freedom from treatment failure rates for older (or elderly) patients with HL, most commonly defined as age 60 years, ranged from 30% to 40% with 5-year overall survival (OS) rates of 40% to 50%. These rates are markedly inferior compared with patients with HL younger than age 60 years with 5-year event-free survival of 70% to 75% and OS greater than 80% to 85%. An important question is: have outcomes improved for older patients with HL with refined therapeutic regimens and enhanced supportive care measures in the contemporary era...
Journal of Clinical Oncology , éditorial en libre accès, 2013